Comet Therapeutics

Lifesaving treatments from the heart of cell biology through our CoMet™ Platform.

[Pearl Freier @PearlF]

Series A panel includes @CometTx1 CEO @ddegraaf , Cedilla Therapeutics CEO Sandra Glucksmann, Tuned Therapeutics CEO Mike Pavia, Deerfield Management's Gilman Megeed #LSXUSA

[Comet Therapeutics @CometTx1]

We are a #biopharmaceutical company developing innovative metabolite replacement therapies for disorders of #Coenzyme A metabolism. Click on the link https://t.co/trQWgBKtR3 to learn more about #CareerOpportunities or to inquire about partnering with us. #LetsDoThis

[Massachusetts Life Sciences Center @MALifeSciences]

A key marker for the overall strength and vitality of our #LifeSciences ecosystem is the health and viability of #EarlyStage enterprises in #Massachusetts.

The MLSC is proud to announce more than $1.9 million in funding to support 10 early-stage life sciences companies in MA.

[Massachusetts Life Sciences Center @MALifeSciences]

The funding is through the MLSC’s Milestone Achievement Program (MAP), which addresses the needs of early-stage life sciences companies by providing grant funding to execute critical, value-creating technical milestones.

🔗 https://t.co/YmHzd0Xyly

[Kendall Square Association @kendallnow]

KSA Member, @MassBio, recently released a report stating that jobs in the Massachusetts Biotech sector grew faster than it had in 2018 in more than a decade. What's essential to sustain that growth? A functioning transportation system. #OurMove #FixTheT https://t.co/MB9CfjCj6y

[LabCentral @LabCentral]

What’s driving the Boston “BioBoom”? From leading college campuses to top-notch hospitals, @WBUR highlights why @LabCentral’s stomping grounds, #KendallSquare has become a hub for #biotech advancement. #WhereBiotechBegins

https://t.co/qDWKsLf4Hv

[Comet Therapeutics @CometTx1]

Get to know our team: Arthur Taveras, our CSO. Art comes with an impressive track record having discovered 14 drug candidates which advanced into development. With specific expertise in designing novel drug candidates for challenging biological targets-Art is an asset to our team

[Comet Therapeutics @CometTx1]

Did you know? Comet Therapeutics, a company built around the unique ability to re-engineer Coenzyme A (CoA)-related metabolism, has raised $28.5 million in Series A funding to develop a broad portfolio of drug candidates. The round was co-led by @CanaanPartners & @SofinnovaParis

[Acies Bio @AciesBio]

We are proud that Enej Kuščer and team at @CometTx1 is writing a sucess story with development of novel drugs for #metabolic disorders!

[Comet Therapeutics @CometTx1]

Get to know our team 👉🏼 Enej Kuscer, @CometTx1 Founder and CTO. Enej is a serial #entrepreneur. He is also the co-founder & #chairman of @AciesBio. Enej's focus is to develop innovative metabolite replacement therapies for rare, genetic neurological diseases.

[Comet Therapeutics @CometTx1]

Get to know our team👉🏼"I have the immodest goal of believing I can change the underpinnings of research and development of pharmaceuticals in order to provide integrative, personalized patient care in all therapeutic areas." David de Graaf, Ph.D., our #President and #CEO. #BHAG

[Comet Therapeutics @CometTx1]

Dysregulated #CoA metabolism plays a key factor in conditions with neuro-metabolic and immuno-metabolic origins. Comet Therapeutics @CometTx1 addresses these profound unmet medical needs with its #CoEnzyme #Metabolism (CoMET™) Platform.

[Comet Therapeutics @CometTx1]

What is CoEnzyme A (CoA)? It is essential in numerous cellular processes including the metabolism of fatty acids, amino acids & sugars; the regulation of gene expression; mitochondrial health & the proper functioning of the TCA cycle, which provides the energy cells need to live.

[Comet Therapeutics @CometTx1]

The proprietary CoMET™ Platform enables precise targeting of specific #CoA species to diseased tissues & organelles within cells where these species are depleted, thereby restoring normal #CellularMetabolism & regulation that underlie basic human health. https://t.co/IfqGvsxNt1

[Comet Therapeutics @CometTx1]

Comet Therapeutics Soars Out of Stealth Mode With $28.5 million Series A Co-led by Canaan and Sofinnova Partners https://t.co/8SFohG59GM

[MassBio @MassBio]

What new opportunities for #patients & #DrugDiscovery will come from the convergence between #DigitalHealth & the #LifeSciences? Find out during our #DigitalHealthImpact2019 on 9/9, part of #BiotechWeekBoston. Register here: https://t.co/iOraYwVpVt

[Comet Therapeutics @CometTx1]

Using our proprietary CoMET Platform of a growing pipeline of next-generation therapeutics, @CometTx1 aspires to treat patients suffering from metabolic, neurological & immunological disorders in which dysregulated CoA plays a role. Stay tuned 💛 #dysregulatedCoA #RareDisease

[Comet Therapeutics @CometTx1]

https://t.co/GIaCKcqfrz